HEALTH NEWS
Study Title:
Risk of systemic toxicity with topical lidocaine/prilocaine: a review.
Study Abstract
The eutectic mixture of lidocaine and prilocaine (EMLA, APP Pharmaceuticals, LLC.) is an anesthetic cream frequently used by dermatologists. Although side effects of EMLA are usually mild local skin reactions (ie, edema, pallor, erythema), more severe complications can be encountered including methemoglobinemia, central nervous system toxicity, and cardiotoxicity. This article reviewed the literature regarding risk of systemic toxicity associated with use of EMLA in the pediatric and adult population. All 12 clinical trials evaluating the safety of EMLA in either the pediatric or adult population generally followed dosing and administration guidelines set by the manufacturer and reported clinically insignificant plasma levels of methemoglobin, lidocaine, prilocaine, and their respective metabolites. To date, nine pediatric cases and three adult cases of systemic toxicity associated with EMLA have been published. Possible factors that contributed to the development of systemic toxicity include excessive amount of EMLA, large application area, prolonged application time, diseased and/or inflamed skin (eg, vascular malformations, molluscum contagiosum, eczema, previously abraded skin), age less than 3 months, prematurity, and concomitant use of a methemoglobin-inducing agent. Recommendations are provided on how to safely use EMLA to minimize the risk of systemic toxicity.
Study Information
Send to J Drugs Dermatol. 2014 Sep;13(9):1118-22.Full Study
https://www.ncbi.nlm.nih.gov/pubmed/25226014Recent News
Arabinogalactan Boosts Lymph Flow and Immunity
Protect Your Gut Mucosal Barrier for Immune Health and Vitality
The Truth About Sugar Substitutes: Are Stevia, Sucralose, and Saccharin Safe?
Boost Your Digestive Power for Better Nutrient Absorption and Gut Health
MTHFR Gene and The Importance of Methyl B12 and Methyl Folate